MRD / ctDNA / DTP: from detection to treatment decisions
Nivolumab, pembrolizumab and durvalumab sit in this direction not as new drugs, but because perioperative IO trials wrote ctDNA into the stratification.
Shattering resistance in resectable NSCLC!
Fresh data from #AACR26 reveals the power of targeting the Adenosine pathway.
The Phase 2 MATISSE trial shows that adding the novel anti-CD39 antibody (IPH5201) to Durvalumab + Chemo achieves a profound 50% pCR in high PD-L1 ($\ge$50%) tumors!
By blocking CD39, we stop ATP degradation and lift immune suppression.
#NSCLC #LungCancer #Immunotherapy #Oncology #MedTwitter #AACR2026
Heat 11 · 6 likes · 0 replies · 5 reposts
Sukeshi Patel Arora, Lorena Fuentes, James Denno, Jennifer Moseley, Brittany M. Altermatt, Elizabeth Diaz, Joshua Ray Smith, Joel Michalek, Lei Zheng
Read the abstract →Mailin Li, Xen Ping Hoi, Jenying Deng, Junjun Zheng, Rabia Hashmani, Recep Bayraktar, Wei Qian, Jianying Zhou, Jian Guan, Kai Sun, Hanh Mai, Tiffany Sheu, Susan Haley, Mary Schwartz, Sunil Mathur, Stephen T. Wong, Fotis Nikolo, Keith Syson Chan, Polly Niravath, Jenny C. Chang
Read the abstract →Alberto Giovanni Leone, Alessandra Raimondi, Paolo Manca, Sabina Murgioni, Giovanni G. Cardellino, Alessandro Bittoni, Antonia Strippoli, Maria Bencivenga, Federica Palermo, Floriana Nappo, Silvio K. Garattini, Thereasa Rich, Gaia Rebecchi, Roberta Fazio, Camilla Damonte, Margherita Ambrosini, Cecilia Villa, Greta Gronchi, Sara Lonardi, Filippo Pietrantonio
Read the abstract →Fabrice Barlesi, Tibor Csoszi, Renata Duchnowska, Thomas Egenod, Laurent Greillier, Amanda Psyrri, Maurice Perol, Herve Lena, Agnes Boyer-Chammard, Veronia Todary, Julien Viotti, Pascale André, Carine Paturel, Markus Jensen
Read the abstract →Source: x.com · x.com